MBIO - Mustang Bio, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.05
-0.23 (-3.66%)
At close: 4:00PM EDT

5.92 -0.13 (-2.15%)
Pre-Market: 7:30AM EDT

Stock chart is not supported by your current browser
Previous Close6.28
Open6.12
Bid0.00 x 1000
Ask5.98 x 900
Day's Range5.79 - 6.90
52 Week Range2.18 - 10.20
Volume3,386,163
Avg. Volume827,579
Market Cap168.292M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • Is Mustang Bio the Next Great Biotech Stock?
    InvestorPlaceyesterday

    Is Mustang Bio the Next Great Biotech Stock?

    Do you remember the movie The Boy in the Plastic Bubble starring John Travolta? How about Bubble Boy starring Jake Gyllenhaal? Both were about a child born without an immune system, forced to live in a bubble to avoid contamination from the outside world.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsWell, now, Mustang Bio (NASDAQ:MBIO) has cured eight infants suffering from the "Bubble Boy" immune disorder, sending MBIO stock up as high as $10.20 in pre-Good Friday trading. The question investors are asking themselves today is whether they should get in on the action before it's too late. FOMO is alive and well and living in this micro-cap biotechnology stock. Why MBIO Stock Is a Good Speculative BetAny time a biotech company comes up with a gene therapy that works, there's bound to be excitement surrounding it. Even better if the infants suffered few, if any, side effects from the experimental gene therapy.Mustang Bio is a 2015 spinoff of Fortress Biotech (NASDAQ:FBIO), a company that is run by Lindsay Rosenwald and Michael Weiss, two serial healthcare entrepreneurs, who've spread lots of bets on small companies like Mustang Bio, of which Fortress owns approximately 38%. * 10 High-Yielding Dividend Stocks That Won't Wilt "While I am a biotech entrepreneur, I am also a 'risk manager,' as we have many shots on goal for such small companies," Rosenwald said in an email. "The more shots on goal, theoretically the less risk there is."However, despite the success of the gene therapy to date, it likely won't file for FDA approval until late 2021 or beyond. In the meantime, it's little to no money in -- 2018 income of $561,000 from interest on its cash on hand -- and $31.2 million in operating expenses, such as research and development, out. So, it's likely to burn through $100 million in operating losses before it even files with the FDA. While this might seem like an argument as to why MBIO stock is not a good speculative bet, it's counter-intuitive. Mustang Bio had cash and short-term investments of $61 million at the end of 2017. At the end of 2018, it was down to $34 million, a reduction of around $29 million, not too far off the operating losses for the year. The company announced on March 29, a $20 million venture debt financing agreement at 9% plus the amount by which the one month LIBOR rate exceeds 2.5%. It's currently at 2.48%. With interest rates stalled and possibly heading lower if a recession rears its ugly head, it looks like Mustang Bio's on the hook for about $1.8 million in interest on the loan.That gets it to $54 million on the balance sheet, close to two years worth of operating losses and into 2021. At that point, should everything about MB-107 remain positive, Mustang Bio will have plenty of financing options to get itself through the next two years, including issuing some more MBIO stock. As speculative biotech plays go, Mustang Bio seems like a good one. Why It's NotWhen it comes to biotech investing, there's no sure thing. The company still needs to confirm the benefits of a handful of patients who've received the experimental gene therapy. Those patients could fail to benefit from MB-107, as the others did. In 2020, Mustang Bio takes over the trial program from St. Jude Children's Research Hospital, which is licensing the gene therapy to the company. It's possible, but unlikely, that something could go wrong from a clinical perspective once the trial is in Mustang Bio's hands. However, CEO Manny Litchman doesn't think so. "The data are extraordinary for every single patient," Litchman said. "It's that compelling nature of the data, in particular for those who don't have a matched sibling donor, that we believe will convince the FDA to do this. Of course, just as in life, we don't always get what we want. The FDA could say no to Mustang Bio and then it's back to the drawing board after more than $150 million in losses. The Bottom Line on Mustang Bio StockI'm not a big believer in investing in money-losing companies. However, as Fortress' Rosenwald said, you've got to take a lot of shots in biotech to be successful. The same goes for biotech investing. * Verizon 5G Launch: 12 Things We Know If you can afford to lose your entire investment, I wouldn't see a problem putting down a small wager on MBIO stock. While you're at it, you might put a small amount in Fortress as well to spread your bets and all that cautionary advice. At the time of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post Is Mustang Bio the Next Great Biotech Stock? appeared first on InvestorPlace.

  • Mustang Bio News: MBIO Stock Skyrockets on New ‘Bubble Boy’ Therapy
    InvestorPlace6 days ago

    Mustang Bio News: MBIO Stock Skyrockets on New ‘Bubble Boy’ Therapy

    Mustang Bio news concerning a trial about a new gene therapy for treating "bubbly boy" disease has MBIO stock soaring on Thursday.Source: Shutterstock Mustang Bio (NASDAQ:MBIO) notes that a Phase1/2 clinical trial of a gene therapy to treat XSCID, which is also known as SCID-X1. This therapy results in children not having a proper immune system and being unable to fight off illnesses.According to the Mustang Bio news release, a lentiviral gene therapy was used on infants under two years of age with the bubble boy disease. There are currently 10 infants that have gone through this therapy and the recent results come from eight of those patients.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMustang Bio has found that the lentiviral gene therapy has been a success for the eight patients tracked in the study. These eight patients saw a successful transferring of a normal copy of the IL2RG gene to bone marrow stem cells.All eight of the patients in the study have cleared their previous infections and are now growing normally. Seven of the eight saw CD3+, CD4+ and CD4+ naive T-cell and natural killer normalization within three to four months after treatment. The eighth infant initially had insufficient T cells, but has now normalized. * 5 Dividend Stocks Perfect for Retirees "The results have been very good thus far. We've been able to restore a full immune system pretty quickly," Ewelina Mamcarz, M.D., said in a statement. "All of these patients were able to come off of isolation and they've returned home with immune systems that were fully functional."MBIO stock was up 128% as of noon Thursday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Mustang Bio News: MBIO Stock Skyrockets on New 'Bubble Boy' Therapy appeared first on InvestorPlace.

  • Why Mustang Bio Stock Is On Fire Today
    Motley Fool6 days ago

    Why Mustang Bio Stock Is On Fire Today

    A new gene therapy could be a functional cure for "bubble boy" disease.

  •  ‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement
    Bloomberg6 days ago

     ‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement

    Mustang Bio, backed by health-care serial entrepreneur Lindsay Rosenwald, has licensed the treatment for the rare disease from St. Jude Children’s Research Hospital, where the treatments took place. Mustang Bio is an offshoot of Fortress Biotech Inc., which is run by Rosenwald and fellow entrepreneur Michael Weiss.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

    Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on April 17) ABIOMED, ...

  • MarketWatch6 days ago

    Mustang Bio's stock soars to near 4-fold gain after deal to commercialize 'bubble boy' disease treatment

    Shares of Mustang Bio Inc. blasted off to a near 4-fold gain (up 257%) in premarket trade Thursday, after the biopharmaceutical company said it entered a licensing agreement with St. Jude Children's Research Hospital to develop the lentiviral gene therapy for the treatment of "bubble boy" disease (XSCID) for commercial use. Data from a phase 1/2 clinical trial evaluating the safety and efficacy of a lentiviral vector to transfer a normal copy of the IL2RG gene to bone marrow stem cells in newly diagnosed infants under the age of two with XSCID, showed that bone marrow harvest, busulfan conditioning and cell infusion were well tolerated, all patients cleared previous infections and are growing normally and most patients were discharged from the hospital within one month. "The results have been very good thus far," said Ewelina Mamcarz, assistant member at St. Jude. "We've been able to restore a full immune system pretty quickly." Mustang Bio's stock, which is on track to open at a 1-year high, was down 9.5% year to date through Wednesday. In comparison, the iShares Nasdaq Biotechnology ETF has gained 9.0% and the S&P 500 has advanced 15.7%.

  • Behind the licensing deal for St. Jude's 'bubble boy' disease cure
    American City Business Journals6 days ago

    Behind the licensing deal for St. Jude's 'bubble boy' disease cure

    St. Jude and Mustang Bio's exclusive license agreement for the gene therapy could bring in millions of dollars for the hospital.

  • Financial Times6 days ago

    Stocks to watch: Unilever, Moneysupermarket, Mustang Bio, Indivior

    ● Unilever led the FTSE 100 gainers after its first-quarter sales topped expectations. The maker of Pot Noodle and Domestos bleach posted 3.1 per cent organic sales growth and total revenue of €12.4bn, beating consensus forecasts of 2.8 per cent and €12.2bn respectively, thanks in part to improvement in emerging markets including Brazil. Unilever had underperformed European staples makers in the year to date, rising 10 per cent against a 17 per cent sector advance, said Goldman Sachs.

  • GlobeNewswire7 days ago

    St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the New England Journal of Medicine has published data from St. Jude Children’s Research Hospital (“St. Jude”), the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases. The data comes from a Phase 1/2 clinical trial of a lentiviral gene therapy for the treatment of newly diagnosed infants under two years old with XSCID, also referred to as SCID-X1 and commonly known as bubble boy disease.

  • St. Jude develops cure for ‘bubble boy’ disease
    American City Business Journals7 days ago

    St. Jude develops cure for ‘bubble boy’ disease

    St. Jude has cured 10 children who, until now, would not have lived past a first or second birthday.

  • GlobeNewswire15 days ago

    Mustang Bio to Present at the World Orphan Drug Congress USA 2019

    NEW YORK, April 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • GlobeNewswire23 days ago

    Mustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a $20 million debt financing agreement with Horizon Technology Finance Corporation (HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services and cleantech industries.

  • GlobeNewswirelast month

    Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, March 18, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • GlobeNewswirelast month

    Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference

    NEW YORK, March 13, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen.

  • GlobeNewswire2 months ago

    Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme

    Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, and Nationwide Children’s Hospital (“Nationwide”), one of America’s largest not-for-profit freestanding pediatric health care systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease, announced today that they have partnered and entered into an exclusive worldwide license agreement to develop an oncolytic virus (C134) for the treatment of glioblastoma multiforme. A Phase 1 clinical trial evaluating C134, an attenuated herpes simplex virus type 1 (HSV-1), in recurrent glioblastoma multiforme is being conducted at the University of Alabama at Birmingham (“UAB”).

  • Need To Know: Mustang Bio, Inc. (NASDAQ:MBIO) Insiders Have Been Buying Shares
    Simply Wall St.4 months ago

    Need To Know: Mustang Bio, Inc. (NASDAQ:MBIO) Insiders Have Been Buying Shares

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • GlobeNewswire4 months ago

    Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

    Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MB-102 (CD123 CAR T) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and incurable blood cancer with a median survival of less than 18 months and no standard of care.

  • MBIO: Mustang: A Steed on the Fast Track
    Zacks Small Cap Research4 months ago

    MBIO: Mustang: A Steed on the Fast Track

    Recognized as an innovator in the chimeric antigen receptor (CAR) engineered T cell (CAR-T) space, Mustang Bio (MBIO) has focused its efforts on immuno-oncology indications since its inception in 2015. The company targets both liquid and solid tumors using CAR-T and has built a facility to supply manufactured cell products for clinical trials and commercial production. Despite this emphasis and progress with MB-102, Mustang acquired an existing gene therapy program with promising clinical data and a clear path to registration via expedited pathways.

  • GlobeNewswire5 months ago

    Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy

    NEW YORK, Nov. 28, 2018 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen.

  • GlobeNewswire5 months ago

    Investor Expectations to Drive Momentum within Lawson Products, Kingold Jewelry, Liberty Broadband, Mustang Bio, Artesian Resources, and MYnd Analytics — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 13, 2018 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen.

  • GlobeNewswire6 months ago

    Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope

    First-of-its-kind Phase 1 clinical trial using intraventricular delivery of CAR T cells to brains of patients with HER2-positive breast cancer with brain metastases now.

  • Simply Wall St.6 months ago

    What Investors Should Know About Mustang Bio Inc’s (NASDAQ:MBIO) Financial Strength

    The direct benefit for Mustang Bio Inc (NASDAQ:MBIO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...